《中国医药科学》杂志欢迎您的投稿!.   今天是:        
秦莉,张秋菊▲.达格列净联合利拉鲁肽注射液对糖尿病肾病患者蛋白尿的影响观察[J].中国医药科学,2022,(20):78-81        基金项目:
达格列净联合利拉鲁肽注射液对糖尿病肾病患者蛋白尿的影响观察
Observation on effect of dapagliflozin plus liraglutide injection on proteinuria in patients with diabetic nephropathy
  
DOI:
中文关键词:  达格列净;利拉鲁肽;糖尿病肾病;临床疗效
英文关键词:Dapagliflozin; Liraglutide; Diabetic nephropathy; Clinical efficacy
作者单位
秦莉,张秋菊▲ 广安门中医院南区内分泌科,北京 102600 
摘要点击次数: 56
全文下载次数: 170
中文摘要:
      [摘要] 目的 分析达格列净联合利拉鲁肽注射液治疗糖尿病肾病(DN)的临床疗效及对蛋白尿的影响。 方法 选取广安门中医院南区内分泌科2020年1月至2021年1月收治的180例DN患者,根据随机数表法分为两组,对照组(n=90)给予利拉鲁肽治疗,观察组(n=90)给予达格列净联合利拉鲁肽治疗,比较两组临床疗效、肾功能指标、血清炎症指标、不良反应发生率。 结果 观察组临床总有效率为96.67%,高于对照组的77.78%,差异有统计学意义(P < 0.05)。观察组治疗后血清肌酐(Scr)、尿素氮(BUN)、尿蛋白排泄率(UAER)均低于对照组,差异有统计学意义(P < 0.05)。观察组治疗后血清C反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)、白介素-6(IL-6)均低于对照组,差异有统计学意义(P < 0.05)。观察组不良反应总发生率与对照组比较,差异无统计学意义(P > 0.05)。 结论 达格列净联合利拉鲁肽可有效改善DN患者肾功能,抑制机体炎症因子释放,且联合给药不良反应较少。
英文摘要:
      [Abstract] Objective To analyze the clinical effect of dapagliflozin combined with liraglutide injection on diabetic nephropathy (DN) and its influence on proteinuria. Methods A total of 180 patients with DN admitted to Department of Endocrinology of Guanganmen Traditional Chinese Medicine Hospital South District from January 2020 to January 2021 were randomly divided into two groups. The control group (n=90) was treated with liraglutide, while the observation group (n=90) was treated with dapagliflozin combined with liraglutide. The clinical efficacy, renal function index, serum inflammation index and the incidence of adverse reactions were compared between the two groups. Results The total clinical effective rate of the observation group (96.67%) was higher than that of the control group (77.78%), with statistically significant difference (P < 0.05). After treatment, serum creatinine (Scr), blood urea nitrogen (BUN) and urinary albumin excretion rate (UAER) in the observation group were lower than those in the control group, with statistically significant differences (P < 0.05). After treatment, serum C-reactive protein (CRP), tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) in the observation group were lower than those in the control group, with statistically significant differences (P < 0.05). There was no significant difference in the total incidence of adverse reactions between the observation group and the control group (P > 0.05). Conclusion Dapagliflozin combined with liraglutide can effectively improve the renal function of DN patients, and inhibit the release of inflammatory factors, and the adverse reactions of combined administration are less.
查看全文  查看/发表评论  下载PDF阅读器
关闭
关键词: 中国医药科学 中国医学 中国医学科学 中华医学 医学杂志 临床医学杂志 医学期刊 中国预防医学 中华预防医学 预防医学杂志 中国药学 药学杂志
药理杂志 中国中医 中医杂志 中华中医药 中医药杂志 中国医疗 医疗器械杂志 中国中西医结合 中国医药 医药杂志 医药期刊 医药论文 医学论文 科研论文 职称论文
function PdfOpen(url){ var win="toolbar=no,location=no,directories=no,status=yes,menubar=yes,scrollbars=yes,resizable=yes"; window.open(url,"",win); } function openWin(url,w,h){ var win="toolbar=no,location=no,directories=no,status=no,menubar=no,scrollbars=yes,resizable=no,width=" + w + ",height=" + h; controlWindow=window.open(url,"",win); } &et=065A03FA1B5E9FC336F18ADB829FA079A31993DEA09E7C4C19DA114C6C31B027C56834F055CF206CCD5008ECF9FA03EC1C49E17D796F140F1A0B9A856077C0A6DE0F7CF3807CE647C69CE0E67663C6395FEA41AA7A8CB42E496E5087AE6163280C07550F7A62C1635A92DFF14430573B4FCE34E199715631&pcid=&cid=&jid=&yid=885CEFEC57DA488F&aid=&vid=&iid=A04140E723CB732E&sid=46CB27789995047D&eid=35FC3610259C2B32&fileno=20220909&flag=1&is_more=0">